Feiterna-Sperling Cornelia, Hüseman Dieter, Timme Jens, Bührer Christoph, Obladen Michael
Department of Pediatric Pneumology, Charité, University Medicine Berlin, Berlin, Germany.
Pediatr Infect Dis J. 2008 Jun;27(6):564-7. doi: 10.1097/INF.0b013e318165f1cf.
Pulmonary arterial hypertension (PAH) affects approximately 0.5% of human immunodeficiency virus (HIV)-infected adults with poor prognosis. The effectiveness of highly active antiretroviral therapy for treatment of HIV-related PAH (HIV-PAH) remains controversial. Little is known about the incidence, clinical course, and therapy options for PAH in HIV-1-infected pediatric patients. Here, we report the case of a preterm infant with HIV-related life-threatening PAH, which resolved after initiation of highly active antiretroviral therapy.
肺动脉高压（PAH）影响约0.5%的成人人类免疫缺陷病毒（HIV）感染者，预后较差。高效抗逆转录病毒疗法治疗HIV相关PAH（HIV-PAH）的有效性仍存在争议。关于HIV-1感染儿科患者PAH的发病率、临床病程及治疗选择知之甚少。在此，我们报告一例早产婴儿患有HIV相关危及生命的PAH，在开始高效抗逆转录病毒疗法后病情得到缓解。
